MARSHFIELD ASSOCIATES
โขCIK: 914976โขFiling: Q4 2025
Marshfield Associates, managed by the seasoned duo of John Marsh and Sarah Fielding, is known for its concentrated, high-conviction equity strategy, currently holding 17 positions with a focus on healthcare and consumer staples. Recently, the fund added Pfizer (PGR) and Expeditors International (EXPD), reflecting its bullish stance on healthcare and logistics amid ongoing market volatility.
Total AUM
$5.7B
QoQ Performance
-1.3%
Positions
17
Top 10 Concentration
75.4%
Latest Filing
Q4 2025
Top Holdings Allocation
AZO
PGR
UNH
ROST
CMI
V
MA
ORLY
AZO10.4%
PGR10.1%
UNH9.6%
ROST8.6%
CMI6.8%
V6.3%
MA6.3%
ORLY6.2%
๐ Biggest Buys
๐ Biggest Sells
Sector Breakdown
Other68.7%
Financial12.6%
Healthcare9.6%
Consumer5.7%
Communication3.4%
Changes from Q3 2025
โ14 increased
โ3 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023